SELLAS Life Sciences (SLS) Profit After Tax Growth (5y) (2015 - 2026)

SELLAS Life Sciences (SLS) Profit After Tax Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 SELLAS Life Sciences 1.89 Bn 1.78 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -28.44%
Dec 31, 2025 -15.67%
Sep 30, 2025 -8.71%
Jun 30, 2025 -8.33%
Mar 31, 2025 -7.01%
Dec 31, 2024 1.91%
Sep 30, 2024 -11.09%
Jun 30, 2024 -18.97%
Mar 31, 2024 -16.09%
Dec 31, 2023 9.39%
Sep 30, 2023 -99.94%
Jun 30, 2023 -7.84%
Mar 31, 2023 -6.78%
Dec 31, 2022 -0.75%
Sep 30, 2022 -9.53%
Jun 30, 2022 -7.31%
Mar 31, 2022 -29.48%
Dec 31, 2021 -83.39%
Sep 30, 2021 -10.29%
Jun 30, 2021 -20.66%